dimethyl (E)-but-2-enedioate;(E)-4-methoxy-4-oxobut-2-enoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: dimethyl (E)-but-2-enedioate;(E)-4-methoxy-4-oxobut-2-enoic acid
• 化学式: C11H14O8
• 分子量: 274.22
• InChiKey: LKPKXPDPQKSWAD-VWJMYZPHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.31
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] COCRYSTALS OF DIMETHYL FUMARATE<br/>[FR] CO-CRISTAUX DE DIMÉTHYL FUMARATE
  申请人：XENOPORT INC

  公开号：WO2014205392A1

  公开（公告）日：2014-12-24

  Disclosed herein are cocrystals of dimethyl fumarate and gentisic acid or (+)-camphoric acid. Dimethyl fumarate is a prodrug of methyl hydrogen fumarate. The cocrystals have improved physicochemical properties and are used in treating multiple sclerosis and psoriasis.

  本文公开了二甲基富马酸和间羟基苯甲酸或（+）-樟脑酸的共晶体。二甲基富马酸是甲基氢富马酸的前药。该共晶体具有改善的物理化学性质，并用于治疗多发性硬化症和银屑病。
• METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS
  申请人：XenoPort, Inc.

  公开号：EP2887934A1

  公开（公告）日：2015-07-01
• [EN] METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS<br/>[FR] MÉTHODES D'ADMINISTRATION DU MONOMÉTHYL FUMARATE ET DES PROMÉDICAMENTS ASSOCIÉS PRÉSENTANT DES EFFETS SECONDAIRES RÉDUITS
  申请人：XENOPORT INC

  公开号：WO2014031844A1

  公开（公告）日：2014-02-27

  Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
• [EN] METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF<br/>[FR] PROCÉDÉS D'UTILISATION DE FUMARATE DE MONOMÉTHYLE ET PROMÉDICAMENTS CORRESPONDANTS
  申请人：XENOPORT INC

  公开号：WO2014031901A1

  公开（公告）日：2014-02-27

  Methods of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound selected from: (i) monomethyl fumarate, (ii) a prodrug of monomethyl fumarate, and (iii) combinations thereof, wherein the disease is chosen from balo concentric sclerosis, bronchiolitis obliterans organizing pneumonia, central nervous system vasculitis, Charcott- Marie-Tooth Disease, childhood ataxia with central nervous system hypomyelination, diabetic retinopathy, graft versus host disease, monomelic amyotrophy, neurodegeneration with brain iron accumulation, neurosarcoidosis, pareneoplastic syndromes, subacute necrotizing myelopathy, Susac syndrome and transverse myelitis.
• [EN] METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS<br/>[FR] PROCÉDÉS D'ADMINISTRATION DE FUMARATE DE MONOMÉTHYLE ET PROMÉDICAMENTS À EFFETS SECONDAIRES RÉDUITS LE CONTENANT
  申请人：XENOPORT INC

  公开号：WO2015017762A1

  公开（公告）日：2015-02-05

  Methods of improving patient safety and reducing undesirable side effects for patients considering therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed. In particular, a method of treating a disease in a patient in need of such treatment is provided. The method comprises testing the patient for a propensity for a deficiency in tissue glutathione S-transferase theta 1 enzyme (GSTT1) levels. Thereafter, a therapeutically effective amount of a compound selected from monomethyl fumarate (MMF), a prodrug of monomethyl fumarate, and combinations thereof is administered to the patient. During the treatment of the disease, blood lymphocyte concentration is periodically tested in the patient at a predetermined time interval length that is based on the enzyme level propensity testing result.